EE370 Assessing the Impact of Crossover Adjustment on the Cost-Effectiveness (CE) of Nivolumab Versus Everolimus in Pre-Treated Advanced Renal Cell Carcinoma (ARCC) in the United States (US)
Abstract
Authors
T De M Edmondson-Jones M Dyer F Ejzykowicz JR May M Kurt E Stawowczyk B Baginska S George